Dual inhibition of MEK and HER3, obtained by combining trametinib and patritumab, determined the complete inhibition of both ERK and AKT signaling pathways resulting in a severely impaired viability of CRC cells. This evidence concerns the gene MAP2K7 and colorectal carcinoma.